AndrewDavidFesnakMD

Blood Banking & Transfusion Medicine, Transplantation Immunology, Anatomic Pathology, Clinical Pathology

Clinical Pathology Resident Physician- PGY2

Dr. Fesnak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3400 Spruce St.
3 Ravdin Building
Philadelphia, PA 19104
Phone+1 215-662-3225

University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 2011 - 2015
Rutgers Robert Wood Johnson Medical SchoolClass of 2011
University of Pennsylvania Health SystemFellowship, Blood Banking/Transfusion Medicine

PubMed

836 citations
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis, Adam D. Cohen, Kristy L. Weber
Science. 2020-02-28
725 citations
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak, Carl H. June, Bruce L. Levine
Nature Reviews. Cancer. 2016-09-01
90 citations
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Mohamed Abou-El-Enein, Magdi Elsallab, Steven A. Feldman, Andrew D. Fesnak, Helen E. Heslop
Blood Cancer Discovery. 2021-08-03

Abstracts/Posters

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
Andrew Fesnak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to El...
Andrew Fesnak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019